BofA warns Fed risks policy mistake with early rate cuts
Burlington (NYSE:BURL), MA – Lawrence J. Jasinski, a director at LeMaitre Vascular Inc . (NASDAQ:LMAT), a $1.86 billion market cap medical device company with a strong financial health rating according to InvestingPro, recently sold shares of the company’s stock, according to a filing with the Securities and Exchange Commission. On March 4, Jasinski sold a total of 3,142 shares at a price of $92.00 per share, amounting to a total transaction value of $289,064. Following this sale, Jasinski holds 2,607 shares of LeMaitre Vascular, a company known for its surgical and medical instruments. The stock, which has declined nearly 13% over the past week and trades at 42.5x earnings, has maintained dividend increases for 14 consecutive years. InvestingPro analysis suggests the stock is currently trading above its Fair Value, with additional insights available in the comprehensive Pro Research Report.
In other recent news, LeMaitre Vascular reported strong fourth-quarter 2024 earnings, with earnings per share (EPS) reaching $0.49, exceeding the forecast of $0.46. Revenue for the quarter came in at $55.7 million, slightly above expectations. JMP Securities responded to these results by raising the company’s price target to $113, citing consistent financial performance and strategic initiatives. Conversely, both Barrington Research and Oppenheimer downgraded LeMaitre’s stock rating from Outperform to Market Perform and Perform, respectively, due to valuation concerns and doubts about the sustainability of price increases.
LeMaitre’s revenue guidance for fiscal year 2025 is set between $235.4 million and $242.8 million, aligning closely with analyst expectations. The company has also cleared 16 out of 23 product MDR CE marks, with plans to expand its sales force and launch new products in China and Europe. Notably, LeMaitre received approval for XenoSure in China, with sales anticipated to begin in the latter half of 2025. The company’s strategic focus on expanding its sales team and geographic presence has been highlighted as a key factor in its ongoing success.
Despite the positive earnings report, LeMaitre’s stock experienced a decline amid broader market volatility, reflecting investor caution regarding future growth prospects. The company ended the quarter with $300 million in cash and securities, positioning it well for future investments and potential acquisitions. Analysts will continue to monitor LeMaitre’s performance, particularly in light of its ambitious expansion plans and the competitive pressures within the vascular device market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.